Jellyfish Venom Yields Potent Blood Pressure-Lowering Peptides
Two novel peptides from jellyfish venom showed potent competitive ACE inhibition with IC50 values of 5.68 and 23.81 µM.
Quick Facts
What This Study Found
Two jellyfish venom peptides competitively inhibit ACE with IC50 values of 5.68 µM (IGDEPRHQYL) and 23.81 µM (IVGRPLANG), confirmed by molecular dynamics.
Key Numbers
IVGRPLANG: IC50 23.81 uM, Ki 51.38 uM; IGDEPRHQYL: IC50 5.68 uM, Ki 5.45 uM; both competitive inhibitors.
How They Did This
In vitro ACE inhibition kinetics (Lineweaver-Burk), IC50 determination, and molecular dynamics simulations.
Why This Research Matters
Marine organisms are an underexplored source of bioactive peptides — jellyfish venom could yield novel antihypertensive drug leads.
The Bigger Picture
Marine bioprospecting continues to yield novel drug candidates, with jellyfish venom joining the growing list of ocean-derived pharmaceutical sources.
What This Study Doesn't Tell Us
In vitro and computational study — oral bioavailability, stability in blood, and in vivo efficacy are unknown.
Questions This Raises
- ?Could these peptides be developed into oral antihypertensive drugs?
- ?Do they survive gastrointestinal digestion?
Trust & Context
- Key Stat:
- IC50 5.68 µM The more potent jellyfish venom peptide IGDEPRHQYL shows strong competitive ACE inhibition
- Evidence Grade:
- In vitro and computational study — strong biochemical characterization but no animal or human testing.
- Study Age:
- Published in 2025, continuing the exploration of marine-derived bioactive peptides.
- Original Title:
- Characterization of Novel ACE-Inhibitory Peptides from Nemopilema nomurai Jellyfish Venom Hydrolysate: In Vitro and In Silico Approaches.
- Published In:
- Marine drugs, 23(7) (2025)
- Authors:
- Prakash, Ramachandran Loganathan Mohan, Ravi, Deva Asirvatham, Hwang, Du Hyeon, Kang, Changkeun, Kim, Euikyung
- Database ID:
- RPEP-13102
Evidence Hierarchy
Frequently Asked Questions
Can jellyfish venom lower blood pressure?
Peptides from jellyfish venom potently inhibit ACE (the same enzyme targeted by common BP drugs like lisinopril), but human studies are needed.
How do ACE-inhibitory peptides work?
They block the enzyme that converts angiotensin I to angiotensin II, which constricts blood vessels — the same mechanism as prescription ACE inhibitor drugs.
Read More on RethinkPeptides
Cite This Study
https://rethinkpeptides.com/research/RPEP-13102APA
Prakash, Ramachandran Loganathan Mohan; Ravi, Deva Asirvatham; Hwang, Du Hyeon; Kang, Changkeun; Kim, Euikyung. (2025). Characterization of Novel ACE-Inhibitory Peptides from Nemopilema nomurai Jellyfish Venom Hydrolysate: In Vitro and In Silico Approaches.. Marine drugs, 23(7). https://doi.org/10.3390/md23070267
MLA
Prakash, Ramachandran Loganathan Mohan, et al. "Characterization of Novel ACE-Inhibitory Peptides from Nemopilema nomurai Jellyfish Venom Hydrolysate: In Vitro and In Silico Approaches.." Marine drugs, 2025. https://doi.org/10.3390/md23070267
RethinkPeptides
RethinkPeptides Research Database. "Characterization of Novel ACE-Inhibitory Peptides from Nemop..." RPEP-13102. Retrieved from https://rethinkpeptides.com/research/prakash-2025-characterization-of-novel-aceinhibitory
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.